Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease

• Published in: Journal of the Formosan Medical Association Vol. 123; no. 4; pp. 517 - 522
• Main Authors: Wu, Kun-Lang, Lin, Ming-Tai, Chang, Yu-Jun
• Format: Journal Article
• Language: English
• Published: Singapore Elsevier B.V 01.04.2024; Elsevier
• Subjects: Intravenous immunoglobulin; Kawasaki disease; Vasculitis; Intravenous immunoglobulin; Kawasaki disease; Vasculitis
• ISSN: 0929-6646; 1876-0821
• DOI: 10.1016/j.jfma.2023.11.014

To investigate whether two brands of intravenous immunoglobulin (IVIG) from the same manufacturer lead to varied effects when administered to patients with Kawasaki disease. (KD) Clinical characteristics, laboratory data, IVIG response, and coronary arteries change were analyzed between two groups. We included 158 KD cases. The mean age at KD diagnosis was 23 ± 1.39 (range, 2–95) months. In the first IVIG course, 18 (11.4 %) patients were unresponsive. TBSF (brand T) and Privigen (brand P) were administered to 94 and 64 patients, respectively. The brand P group had a significantly longer fever (P < 0.001) and hospitalization (P = 0.007) durations after the therapy and a higher number of IVIG unresponsiveness (P = 0.016) than the brand T group. In the multivariate logistic regression analysis, a high Formosa score (≥3, Odds ratio [OR], 4.939; 95 % confidence interval [CI], 1.199–20.337; P = 0.027), high levels of CRP (≥12 mg/L, OR: 4.257,95 % CI,1.265–14.322; P = 0.019), and treatment with brand P (OR, 3.621; 95 % CI, 1.029–12.677; P = 0.045) were independent risk factors for IVIG unresponsiveness. Compared with brand T, brand P prolonged the fever and hospitalization durations after IVIG treatment and increased the proportion of IVIG treatment unresponsiveness, but it did not infer the coronary arteries sequelae.